
    
      An open-label, long-term study to evaluate the safety of inhaled nitric oxide (iNO) in
      subjects with pulmonary arterial hypertension (PAH) who participated in IK-7001-PAH-201 and
      PULSE-PAH-004 to provide these patients with continued access to chronic iNO until the time
      of approval or development of iNO in PAH is discontinued.
    
  